The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Abstract
PURPOSE: The HER-2/neu gene codes for a membrane receptor protein that is homologous, but distinct from the epidermal growth factor receptor. This investigation was performed to validate fluorescence in situ hybridization (FISH) as a sensitive and specific method for assessing HER-2/neu gene amplification in archival tissue and to test whether this alteration is associated with poor prognosis. MATERIALS AND METHODS: HER-2/neu gene amplification was determined by FISH in 140 archival breast cancers, previously characterized for gene amplification by Southern hybridization or dot-blot hybridization, and for gene expression by Northern hybridization, Western immunoblot, or immunohistochemistry. A separate cohort of 324 node-negative breast cancers was assessed for amplification by FISH to determine the utility of HER-2/neu gene amplification. RESULTS: Relative to solid-matrix blotting procedures, FISH analysis of HER-2/neu gene amplification showed a sensitivity of 98% and a specificity of 100% in 140 breast cancers. Among patients treated by surgery only, the relative risks (relative hazard) of early recurrence (recurrent disease within 24 months of diagnosis), recurrent disease (at any time), and disease-related death were statistically significantly associated with amplification. The prognostic information contributed by HER-2/neu amplification was independent of the other markers studied. CONCLUSION: FISH was an alternative technique for determining gene amplification and had some distinct advantages over Southern hybridization. Our results demonstrate that HER-2/neu gene amplification in the absence of adjuvant therapy is an independent predictor of poor clinical outcome and is a stronger discriminant than tumor size. Women with small tumors that had gene amplification were at increased risk of recurrence and disease-related death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
Shih, C., Padhy, L. C., Murray, M., & Weinberg, R. A. (1981) · Nature · doi:10.1038/290261a0 · Cited by 791
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 622
Semba, K., Kamata, N., Toyoshima, K., & Yamamoto, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6497 · Cited by 598
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 554
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
Self-citationAllred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Self-citationDrebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 400
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T. S., & Yokota, J. (1989) · PubMed · Cited by 341
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1991) · PubMed · Cited by 261
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Borg, Å., Baldetorp, B., Fernö, M., Killander, D., Olsson, H., Ryden, S., & Sigurdsson, H. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90194-5 · Cited by 246
Press, M. F., Pike, M. C., Hung, G., et al. (1994) · PubMed · Cited by 222
Self-citationBerns, E., Klijn, J. G. M., van Putten, W. L., van Staveren, I. L., Portengen, H., & Foekens, J. A. (1992) · PubMed · Cited by 201
ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg, Å., Baldetorp, B., Fernö, M., Killander, D., Olsson, H. L., & Sigurdsson, H. (1991) · PubMed · Cited by 188
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
Saffari, B., Jones, L. A., El‐Naggar, A. K., et al. (1995) · PubMed · Cited by 145
Self-citationThe relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
O'Reilly, S., Barnes, D. M., Camplejohn, R., Bártková, J., Gregory, W. M., & Richards, M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.102 · Cited by 130
Fieller's Theorem, the Likelihood and the Delta Method
Cox, C. (1990) · Biometrics · doi:10.2307/2532090 · Cited by 95
Cited by
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationRace, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citation
Metadata
- Authors
- Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R., & Flom, K. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-08
- Volume
- 15
- Issue
- 8
- Pages
- 2894-2904
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1867197625
- Cited by
- 802
- References
- 33
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.